Patents by Inventor Artur Mitterer

Artur Mitterer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9441203
    Abstract: A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: September 13, 2016
    Assignee: Baxalta Innovations GmbH
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner, Leopold Grillberger, Artur Mitterer
  • Patent number: 9315560
    Abstract: The present invention provides methods for purifying Von Willebrand factor (VWF) for increased removal of non-lipid enveloped viruses.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: April 19, 2016
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christa Mayer
  • Publication number: 20160068587
    Abstract: The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine. The invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/L of a polyamine.
    Type: Application
    Filed: November 16, 2015
    Publication date: March 10, 2016
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Artur Mitterer
  • Publication number: 20160060603
    Abstract: The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool.
    Type: Application
    Filed: January 23, 2015
    Publication date: March 3, 2016
    Inventors: Manfred Reiter, Leopold Grillberger, Wolfgang Mundt, Artur Mitterer, Horst Schafhauser
  • Publication number: 20160039869
    Abstract: The present invention relates to a method for the purification of Vitamin K dependent proteins with high yield and high purity, particularly enriched in active protein, on anion exchange resin materials, to Vitamin K dependent proteins obtainable by said method, and to a kit comprising means for carrying out said method.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 11, 2016
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler, Dominik Mittergradnegger
  • Patent number: 9127264
    Abstract: The present invention relates to recombinant furin (rFurin) and methods for producing rFurin. More specifically, the invention relates to substantially animal protein-free rFurin and methods for producing substantially animal protein-free rFurin.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: September 8, 2015
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Barbara Plaimauer, Simone Von Fircks, Leopold Grillberger, Meinhard Hasslacher, Roland Geyer, Artur Mitterer, Manfred Reiter
  • Publication number: 20150104849
    Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 16, 2015
    Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
  • Publication number: 20150072415
    Abstract: A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate.
    Type: Application
    Filed: March 31, 2014
    Publication date: March 12, 2015
    Applicant: Baxter Innovations GmbH
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner, Leopold Grillberger, Artur Mitterer
  • Patent number: 8969533
    Abstract: The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: March 3, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Manfred Reiter, Leopold Grillberger, Wolfgang Mundt, Artur Mitterer, Horst Schafhauser
  • Patent number: 8945895
    Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: February 3, 2015
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
  • Publication number: 20140302591
    Abstract: The present invention relates to a two-step method for the purification of divalent cation binding proteins with high yield and high purity on anion exchange resin materials, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.
    Type: Application
    Filed: October 12, 2012
    Publication date: October 9, 2014
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fielder
  • Publication number: 20140302592
    Abstract: The present invention relates to a two-step method for the purification of divalent cation binding proteins with high yield and high purity on anion exchange resin materials, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.
    Type: Application
    Filed: October 12, 2012
    Publication date: October 9, 2014
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
  • Patent number: 8722406
    Abstract: A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: May 13, 2014
    Assignee: Baxter Innovations GmbH
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner, Leopold Grillberger, Artur Mitterer
  • Publication number: 20130344535
    Abstract: The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m2.
    Type: Application
    Filed: June 19, 2013
    Publication date: December 26, 2013
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Wolfgang Mundt, Artur MITTERER, Manfred REITER, Meinhard HASSLACHER, Leopold GRILLBERGER, Thomas KRElL
  • Patent number: 8399632
    Abstract: The present invention relates to a method for the purification of rFIX using anion exchange chromatography in the pseudo-affinity mode, wherein said method comprises a wash step with a wash buffer having a salt concentration of more than 200 mM. The purification according to the invention provides a method to enrich rFIX molecules which have been posttranslationally modified by sulfation and/or phosphorylation. The present invention further relates to purified rFIX compositions enriched in monosulfated and/or monophosphorylated rFIX molecules.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: March 19, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
  • Patent number: 8388847
    Abstract: The invention relates generally to methods of concentrating mixtures including shear sensitive biopolymers, such as von Willebrand Factor. Conventional methods of concentrating biopolymers impart too much shear stress, which causes the degradation of shear sensitive biopolymers. The methods disclosed herein reduce the shear stress while maintaining a high rate of filtrate flux. Disclosed herein is a method for concentrating shear sensitive biopolymers including flowing a mixture with a shear sensitive biopolymer into a hollow fiber dialysis module to form a retentate having a shear sensitive biopolymer concentration that is greater than that of the mixture. Hollow fiber dialysis modules have high filtrate fluxes and low shear rates at low flow rates. This ensures a high product yield and minimal loss of shear sensitive biopolymers.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: March 5, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christa Mayer
  • Patent number: 8389261
    Abstract: The present invention provides methods of isolation and purification of Streptomyces griseus trypsin (SGT) from PRONASE protease mixture in a single affinity chromatography step and uses of the purified SGT.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: March 5, 2013
    Assignee: Baxter Healthcare S.A.
    Inventors: Artur Mitterer, Christa Tauer, Manfred Reiter, Wolfgang Mundt
  • Publication number: 20120108513
    Abstract: The present invention relates to a method for the purification of divalent cation binding proteins with high purity on an anion exchange resin material, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.
    Type: Application
    Filed: April 29, 2011
    Publication date: May 3, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
  • Patent number: 8148502
    Abstract: The present invention relates to a method for obtaining highly purified recombinant alpha1-antitrypsin (rAAT) using anion exchange chromatography, wherein a composition comprising rAAT and at least one impurity originating from cultivation of cells used for generating of rAAT is loaded onto a column containing anion exchange material and the anion exchange chromatography is carried out with buffers containing phosphate ions and N-acetylcysteine.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: April 3, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
  • Patent number: 8143347
    Abstract: The present invention relates to a proteinaceous construct comprising a blood coagulation factor, e.g., Factor VIII (FVIII), being bound to at least one water soluble polymer, including a poly(alkylene oxide) such as polyethylene glycol (PEG). Further the present invention relates to methods of preparing PEGylated blood coagulation factor, e.g., FVIII, in the presence of bound antibodies. The invention also relates to methods for prolonging the in vivo-half-life of blood coagulation factor, e.g., FVIII, in the blood of a mammal having a bleeding disorder associated with functional defects or deficiencies of blood coagulation factor, e.g., FVIII.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: March 27, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Artur Mitterer, Michael Graninger, Meinhard Hasslacher